The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BRCA reversion mutations in a pan-cancer cohort to reveal BRCA-dependence in select noncanonical BRCA-mutant histologies.
 
Yonina R. Murciano-Goroff
Travel, Accommodations, Expenses - AstraZeneca
 
Alison M. Schram
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Kura Oncology (Inst); Lilly (Inst); Merus (Inst); Northern Biologics (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Surface Oncology (Inst)
 
Ezra Rosen
No Relationships to Disclose
 
Yelena Y. Janjigian
Stock and Other Ownership Interests - Rgenix
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Imugene; Jounce Therapeutics; Lilly; Merck; Merck Serono; Merck Sharpe and Dohme Corp.; Michael J. Hennessy Associates; Ono Pharmaceutical; Pfizer; Rgenix; Seagen; Zymeworks
Research Funding - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Lilly; Merck; Rgenix (Inst); Roche
Other Relationship - Axis Medical Education; Clinical Care Options; Paradigm; Research to Practice
 
Michael F. Berger
Research Funding - Grail
Patents, Royalties, Other Intellectual Property - Provisional patent pending for "Systems and Methods for Detecting Cancer via cfDNA Screening"
 
Mark Donoghue
No Relationships to Disclose
 
Chaitanya Bandlamudi
No Relationships to Disclose
 
Alexander E. Drilon
Honoraria - Foundation Medicine; Medscape; MORE Health; OncLive; Peerview; PeerVoice; Physicans' Education Resource; Research to Practice; Targeted Oncology
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Archer; AstraZeneca; Bayer; BeiGene; BerGenBio; Blueprint Medicines; EMD Serono/Merck; Exelixis; Genentech/Roche; Helsinn Therapeutics; Hengrui Therapeutics; Ignyta; Lilly; Loxo; Melendi; Monopteros Therapeutics; Monopteros Therapeutics; MORE Health; Novartis; Pfizer; Remedica; Repare Therapeutics; Takeda/Millennium; TP Therapeutics; Tyra Biosciences; Verastem; Verastem
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - GlaxoSmithKline; Merck; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva